Relmada Therapeutics (RLMD) announced the initiation of dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. “Dosing of the first subjects in the Phase 1 study is an important milestone for REL-P11, a low-dose, modified-release psilocybin formulation. Preclinical rodent studies, published at the American Association for the Study of Liver Disease in 2023, showed that treatment with REL-P11 improved multiple metabolic parameters with no detrimental CNS effects, and suggest that REL-P11 could have potential to become a valuable therapeutic option in the evolving obesity and metabolic syndrome space,” said Sergio Traversa, Chief Executive Officer of Relmada. “We expect the Phase 1 study to help define the pharmacokinetic, safety and tolerability profile of REL-P11 and, with positive data, pave the way for a Phase 2a proof-of-concept study to begin in H1 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RLMD:
- Relmada Therapeutics Inc. Reports Q3 2024 Financial Results
- Relmada Therapeutics reports Q3 EPS (72c), consensus (64c)
- Rising High: Exclusive talk with house of brands Carma HoldCo
- RLMD Upcoming Earnings Report: What to Expect?
- Rising High: RIV Capital provides update on revenue, synergy realization
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
